Yonsei Med J.  2017 Jul;58(4):867-871. 10.3349/ymj.2017.58.4.867.

Effect of Early Plasma Exchange on Survival in Patients with Severe Fever with Thrombocytopenia Syndrome: A Multicenter Study

• Oh WS
• Yoo JR
• Kwon KT
• Kim HI
• Lee SJ
• Jun JB
• Ryu SY
• Kim HA
• Hur J
• Wi YM
• Lim MH
• Heo ST

• KMID: 2419096
• DOI: http://doi.org/10.3349/ymj.2017.58.4.867

Abstract

Despite a high mortality rate, no specific treatment for severe fever with thrombocytopenia syndrome (SFTS) has been established. This study compared the clinical outcomes of SFTS patients treated with plasma exchange (PE group) with those who were not treated (non-PE group) at nine Korean hospitals between May 2013 and August 2015. A total of 53 SFTS patients were included: 24 (45.3%) PE cases and 29 (54.7%) non-PE cases. The overall in-hospital mortality rate was 32.1% (17/53). The in-hospital mortality rate of the PE group did not differ from that of the non-PE group (29.3% vs. 34.5%, p=0.680). Of the 24 PE cases, 16 (66.7%) were treated with PE within 7 days of symptom onset (early PE group). The early PE group survived longer than the non-PE group (mean 28.4 days vs. 22.6 days, p=0.044). Multivariate analysis showed an inverse association between early PE implementation and 30-day mortality (adjusted hazard ratio 0.052, 95% confidence interval 0.004-0.678, p=0.024). The results of this study suggest that early PE implementation may have a beneficial effect on the clinical outcome of SFTS patients.

Keyword

Severe fever with thrombocytopenia syndrome; Phlebovirus; plasma exchange; treatment

MeSH Terms

Aged
Female
Fever/*complications/*mortality
Humans
Male
Middle Aged
Multivariate Analysis
Plasma Exchange/*mortality
Risk Factors
Survival Analysis
Thrombocytopenia/*complications/*mortality
Treatment Outcome

Figure

• 

  Fig. 1 Comparison of 30-day survival between treatment groups. (A) PE group vs. non-PE group. There was no significant difference in 30-day survival between the two groups (mean survival time 24.0 days vs. 22.6 days, p=0.622 by the log-rank test). (B) Early PE group vs. non-PE group. Survival was longer in the early PE group than in the non-PE group (mean survival time 28.4 days vs. 22.6 days, p=0.044 by the log-rank test). PE, plasma exchange.

Reference

1. Li DX. Severe fever with thrombocytopenia syndrome: a newly discovered emerging infectious disease. Clin Microbiol Infect. 2015; 21:614–620. PMID: 25769426.

2. Liu Q, He B, Huang SY, Wei F, Zhu XQ. Severe fever with thrombocytopenia syndrome, an emerging tick-borne zoonosis. Lancet Infect Dis. 2014; 14:763–772. PMID: 24837566.

3. Liu S, Chai C, Wang C, Amer S, Lv H, He H, et al. Systematic review of severe fever with thrombocytopenia syndrome: virology, epidemiology, and clinical characteristics. Rev Med Virol. 2014; 24:90–102. PMID: 24310908.

4. Deng B, Zhang S, Geng Y, Zhang Y, Wang Y, Yao W, et al. Cytokine and chemokine levels in patients with severe fever with thrombocytopenia syndrome virus. PLoS One. 2012; 7:e41365. PMID: 22911786.

5. Choi SJ, Park SW, Bae IG, Kim SH, Ryu SY, Kim HA, et al. Severe fever with thrombocytopenia syndrome in South Korea, 2013-2015. PLoS Negl Trop Dis. 2016; 10:e0005264. PMID: 28033338.

6. Oh WS, Heo ST, Kim SH, Choi WJ, Han MG, Kim JY. Plasma exchange and ribavirin for rapidly progressive severe fever with thrombocytopenia syndrome. Int J Infect Dis. 2014; 18:84–86. PMID: 24161209.

7. Park SW, Han MG, Yun SM, Park C, Lee WJ, Ryou J. Severe fever with thrombocytopenia syndrome virus, South Korea, 2013. Emerg Infect Dis. 2014; 20:1880–1882. PMID: 25341085.

8. Gai ZT, Zhang Y, Liang MF, Jin C, Zhang S, Zhu CB, et al. Clinical progress and risk factors for death in severe fever with thrombocytopenia syndrome patients. J Infect Dis. 2012; 206:1095–1102. PMID: 22850122.

9. Zhang YZ, He YW, Dai YA, Xiong Y, Zheng H, Zhou DJ, et al. Hemorrhagic fever caused by a novel Bunyavirus in China: pathogenesis and correlates of fatal outcome. Clin Infect Dis. 2012; 54:527–533. PMID: 22144540.

10. Deng B, Zhou B, Zhang S, Zhu Y, Han L, Geng Y, et al. Clinical features and factors associated with severity and fatality among patients with severe fever with thrombocytopenia syndrome Bunyavirus infection in Northeast China. PLoS One. 2013; 8:e80802. PMID: 24236203.

11. Sun Y, Jin C, Zhan F, Wang X, Liang M, Zhang Q, et al. Host cytokine storm is associated with disease severity of severe fever with thrombocytopenia syndrome. J Infect Dis. 2012; 206:1085–1094. PMID: 22904342.

12. Stegmayr B. Apheresis in patients with severe sepsis and multi organ dysfunction syndrome. Transfus Apher Sci. 2008; 38:203–208. PMID: 18492616.

13. Kim UJ, Kim DM, Ahn JH, Kang SJ, Jang HC, Park KH, et al. Successful treatment of rapidly progressing severe fever with thrombocytopenia syndrome with neurological complications using intravenous immunoglobulin and corticosteroid. Antivir Ther. 2015; 21:637–640.

14. Park SY, Choi W, Chong YP, Park SW, Wang EB, Lee WJ, et al. Use of plasma therapy for severe fever with thrombocytopenia syndrome encephalopathy. Emerg Infect Dis. 2016; 22:1306–1308. PMID: 27315224.

15. Park I, Kim HI, Kwon KT. Two treatment cases of severe fever and thrombocytopenia syndrome with oral ribavirin and plasma exchange. Infect Chemother. 2017; 49:72–77. PMID: 28271646.